Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Does Social Media Use Associate with Vasomotor, Sexual, and Musculoskeletal Symptoms in Breast Cancer Survivors Receiving Endocrine Therapy?

Journal of clinical medicine·2026

Same author

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Current oncology (Toronto, Ont.)·2026

Same author

Corneal Epithelial Alterations Associated With Cyclin-Dependent Kinase 4/6 Inhibitor Therapy in Hormone Receptor-Positive Breast Cancer.

American journal of ophthalmology·2026

Same author

Significant Correlation of Dynamic Pan-Immune Inflammation Value and Magnetic Resonance Imaging Response in Patients with Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy.

Current oncology (Toronto, Ont.)·2026

Same author

Uric Acid-Driven Biomarkers and Clinical Outcomes in Metastatic Pancreatic Cancer: A Multicenter Real-World Cohort Study.

Diagnostics (Basel, Switzerland)·2026

Same author

Pretreatment Lactate Dehydrogenase-to-Albumin Ratio and Clinical Outcomes in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.

Journal of clinical medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

Four different malignancies in one patient: a case report.

Umut Demirci¹, Ugur Coşkun, Pinar Uyar Göçün

¹Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey. ugur.coskun@gazi.edu.tr.

|March 9, 2010

Summary

Cancer survivors face increased risks for new primary cancers. This case highlights a rare instance of a 78-year-old woman developing four distinct adenocarcinomas, including bilateral breast, ovarian, and retroperitoneal neuroendocrine carcinoma.

Related Experiment Videos

Last Updated: Jun 15, 2026

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

Area of Science:

Oncology
Cancer Epidemiology

Background:

Cancer survivors have a statistically significant higher risk of developing new primary cancers compared to the general population.
The occurrence of second primary malignancies is a known phenomenon in cancer survivorship.
Developing third or subsequent primary malignancies is exceptionally rare.

Purpose of the Study:

To report a rare clinical case of metachronous quadruple adenocarcinoma in a cancer survivor.
To discuss the implications of multiple, distinct primary cancers in an aging patient.

Main Methods:

Case report detailing the clinical history, diagnosis, and treatment of a 78-year-old female patient.
Review of relevant literature on metachronous malignancies in cancer survivors.

Main Results:

The patient presented with four distinct primary adenocarcinomas: bilateral breast cancer, ovarian cancer, and retroperitoneal neuroendocrine carcinoma.
This represents a rare occurrence of quadruple metachronous malignancies.

Conclusions:

This case underscores the complex challenges in managing cancer survivors with multiple primary malignancies.
Further research is needed to understand the risk factors and optimal management strategies for extremely rare, high-order metachronous cancers.